SAN FRANCISCO— The orally administered androgen receptor blocker enzalutamide significantly extended both overall survival and radiographically determined progression-free survival in men whose metastatic castration-resistant prostate cancer was asymptomatic or mildly symptomatic and had not been treated with chemotherapy in the phase III PREVAIL study. Dr Tomasz Beer MD, FACP, from Oregon Health & Science University in Portland, USA, presented his group’s findings to the 2014 ASCO Genitourinary Cancers Symposium from 1717 patients randomised to treatment with enzalutamide or placebo. Overall survival was extended by over two months to a median of 32.4 months while progression free survival went up from four to 14 months with the active drug. He discussed the clinical implications with AudioMedica.com.
Dr. Tomasz Beer MD, FACP
Oregon Health & Science University
Hematology and Medical Oncology,
3181 S.W. Sam Jackson Park Rd.
Abstract number: LBA1^
Web link: http://www.asco.org/sites/www.asco.org/files/gu14_lba1.pdf